Zoetis Secures Conditional License for Avian Influenza Vaccine Amid HPAI Challenges

Zoetis Advances Animal Health with Conditional License for Avian Influenza Vaccine

Zoetis, a premier player in the animal health sector, receives a conditional license from the U.S. Department of Agriculture's Center for Veterinary Biologics for its H5N2 subtype Avian Influenza Vaccine, specifically targeting chickens. This significant development comes at a critical time, as the poultry industry grapples with the repercussions of Highly Pathogenic Avian Influenza (HPAI), which has affected over 150 million birds in the U.S. since February 2022. The license approval follows Zoetis’ extensive demonstration of the vaccine's safety, purity, and a promising efficacy based on serological evidence. The decision regarding the vaccination of poultry flocks ultimately rests with national regulatory authorities and the poultry industry itself.

Mahesh Kumar, Ph.D., senior vice president at Zoetis, highlights the company’s proactive stance in responding to the emergence of new strains of HPAI. This recent license builds upon Zoetis's extensive history in developing avian influenza vaccines, dating back to their initial efforts in the early 2000s. Zoetis previously secured a conditional license for the H5N1 vaccine in 2016, which has since been utilized by the U.S. Fish & Wildlife Service to protect endangered species such as the California condor. This consistent innovation illustrates Zoetis's commitment to addressing pressing health threats to poultry and other birds through effective vaccination strategies.

As the poultry industry continues to face challenges from HPAI outbreaks, Zoetis is well-positioned to contribute to the ongoing efforts in avian health management. The company’s existing portfolio, which includes the USDA-licensed POULVAC® FLUFEND™ i AI H5N3 RG vaccine, underscores its robust capabilities in providing solutions tailored to both commercial and conservation needs. With a revenue of $9.3 billion in 2024 and a dedicated workforce of approximately 13,800 employees, Zoetis remains steadfast in its mission to enhance global animal health and welfare through innovative care solutions.

In addition to this recent license, Zoetis’s ongoing commitment to research and development in animal health signifies its role as a key player in the industry. The company’s proactive approach in addressing avian diseases not only supports poultry producers but also contributes to broader ecological health efforts. As avian influenza continues to pose a risk to both domestic and wild bird populations, Zoetis’s advancements in vaccine technology are crucial for safeguarding the future of avian species and ensuring food security in the poultry sector. For more information, Zoetis encourages stakeholders to visit its official website.